The European Medicines Agency has published a report focused on the mid-term achievements of its Regulatory Science Strategy to 2025. The strategy provides a plan for advancing regulatory science over a five-year period to be ready to support the development and assessment of ever more complex medicines that increasingly deliver healthcare solutions by converging different innovative technologies.
The report provides an overview of the main deliverables achieved between March 2020 and December 2022 across the human and veterinary areas.
In the human domain, progress was made in several areas, such as:
- fostering innovation in clinical trials
- promoting use of high-quality, real-world data in decision making
- reinforcing patient relevance in evidence generation
- contributing to health technology assessment bodies’ preparedness and downstream decision making for innovative medicines
- supporting developments in precision medicine, biomarkers and ‘omics
Work will continue in the period 2023-2025 to deliver the strategic goals to their fullest potential.
Read the report here!